10-Q: Actuate Therapeutics Faces Going Concern Despite Positive Cancer Trial Data

Actuate Therapeutics reported promising Phase 2 results for elraglusib in pancreatic cancer but faces substantial doubt about its ability to continue as a going concern beyond October 2025.

Summary

• Actuate Therapeutics, a clinical-stage biopharmaceutical company, is developing elraglusib, a GSK-3 inhibitor for cancer treatment.
• The company announced positive topline Phase 2 clinical trial data for elraglusib in combination with gemcitabine/nab-paclitaxel (GnP) for first-line metastatic pancreatic ductal adenocarcinoma (mPDAC).
• The trial met its primary endpoint, demonstrating a statistically significant improvement in median overall survival (mOS) of 10.1 months versus 7.2 months for GnP alone (HR=0.63, log-rank p=0.01).
• The elraglusib/GnP combination showed a 1-year survival rate of 44.1% compared to 22.3% for GnP alone (p=0.0005), representing a 37% reduction in the risk of death.
• Treatment-emergent adverse events (TEAEs) and Serious Adverse Events (SAEs) were similar between arms, indicating a favorable risk-benefit profile, with transient visual disturbances being the most frequent Grade 1-2 TRAE.
• The company completed a Phase 1/2 clinical trial in refractory pediatric malignancies, identifying Ewing sarcoma (EWS) as a potential second indication.
• Actuate Therapeutics has incurred significant operating losses since inception, with an accumulated deficit of $144,646,278 as of June 30, 2025.
• Cash and cash equivalents stood at $6,492,656 as of June 30, 2025, with a working capital deficit of $2,512,162.
• Management estimates that existing cash and cash equivalents will not satisfy operational and capital requirements beyond October 2025.
• The company's financial condition raises substantial doubt about its ability to continue as a going concern for a year from the filing date.
• Actuate raised $4,621,546 in net proceeds from a June 2025 Private Placement and $2,148,506 in net proceeds from a Committed Equity Facility with B. Riley Principal Capital II during the quarter ended June 30, 2025.
• Subsequent to June 30, 2025, and through August 13, 2025, an additional $1,597,000 in net proceeds was raised under the Committed Equity Facility.

Sentiment

Score: 3

Explanation: While the clinical trial results for elraglusib in mPDAC are highly positive and represent a significant scientific breakthrough, the company's severe financial distress, explicit going concern warning, and very short cash runway (until October 2025) create an immediate and substantial risk to its operational continuity. The positive clinical data is overshadowed by the urgent need for significant capital, leading to a low sentiment score despite the scientific promise.

Positives

• Elraglusib's Phase 2 trial in metastatic pancreatic ductal adenocarcinoma (mPDAC) met its primary endpoint, showing statistically significant improvement in median overall survival (mOS) (10.1 months vs. 7.2 months, HR=0.63, log-rank p=0.01).
• The elraglusib/GnP combination demonstrated a 37% reduction in the risk of death and a significantly higher 1-year survival rate (44.1% vs. 22.3%, p=0.0005).
• Improved 18-month OS (19.7% vs. 4.4%) and 24-month OS (13.8% vs. 0%) were observed in the elraglusib/GnP arm.
• Overall response rates (ORR), median progression-free survival (PFS), and disease control rates (DCR) were numerically improved in the elraglusib/GnP combination arm.
• The safety profile of the elraglusib/GnP combination was favorable, with treatment-emergent and serious adverse events similar to the control arm.
• Ewing sarcoma (EWS) was identified as a potential second indication for elraglusib following the completion of a Phase 1/2 pediatric malignancies trial.
• The company successfully raised $4,621,546 in net proceeds from a private placement and $2,148,506 from a Committed Equity Facility during the quarter, with additional $1,597,000 raised post-quarter end.

Negatives

• The company has a limited operating history and has incurred significant operating losses since inception, with an accumulated deficit of $144,646,278 as of June 30, 2025.
• Cash and cash equivalents of $6,492,656 as of June 30, 2025, are insufficient to fund operations beyond October 2025.
• There is substantial doubt about the company's ability to continue as a going concern for a year from the filing date.
• Net cash used in operating activities increased to $8,792,501 for the six months ended June 30, 2025, from $7,921,220 in the prior year period, indicating increased cash burn.
• General and administrative expenses significantly increased by $4,373,869 for the six months ended June 30, 2025, compared to the prior year period, primarily due to personnel-related expenses and public company costs.

Risks

• The company has a limited operating history, has incurred significant operating losses, and expects to incur significant operating losses for the foreseeable future, with a high risk of never generating revenue or becoming profitable.
• The company's financial condition raises substantial doubt as to its ability to continue as a going concern.
• Substantial additional capital is required in the near term to finance operations; failure to obtain this could force delays, reductions, or termination of development programs or operations.
• Raising additional capital may cause dilution to stockholders, restrict operations, or require relinquishing rights to technologies or product candidates.
• The actual number of shares sold to B. Riley under the Committed Equity Facility or the actual gross proceeds are unpredictable.
• The company does not have, and may never have, any approved products on the market, and its business is highly dependent on receiving regulatory approvals for elraglusib.
• The company currently depends entirely on the success of elraglusib; failure to advance, obtain approval, or commercialize it in a timely manner would materially harm the business.
• There is no guarantee that the FDA will accept the company's New Drug Application (NDA) even if all planned clinical trials are completed.
• Clinical and preclinical drug development is lengthy, expensive, and uncertain, and prior results are not necessarily predictive of future outcomes.
• Use of elraglusib or future product candidates could be associated with side effects, adverse events, or safety risks, potentially delaying or precluding regulatory approval.
• Delays or difficulties in clinical trial enrollment could adversely affect regulatory approvals.
• Interim, topline, and preliminary data from clinical trials are subject to change and verification procedures.
• Termination of third-party licenses could adversely affect rights to important technologies.
• Reliance on a China-based drug substance (DS) manufacturer poses geopolitical risks, potential cost increases, and delays.
• Unfavorable tariffs could increase the cost of elraglusib DS.
• Reliance on third parties to conduct non-clinical studies and clinical trials carries risks if these parties do not perform successfully or meet deadlines.
• Data provided by collaborators and other parties may be inaccurate, misleading, or incomplete.
• Loss of key management or scientific personnel, or inability to recruit qualified employees, may disrupt the business.
• Competition and technological change may make product candidates less competitive or obsolete.
• Actual operating expenses and capital expenditures could differ materially from management's estimates.
• Concentration of ownership by principal stockholders limits influence of others and creates potential for conflicts of interest.
• Current and new investors will experience dilution due to future sales or issuances of common stock.
• The trading price of common stock could be highly volatile.
• Substantial sales of shares by existing stockholders (e.g., from IPO lock-up expiry, Committed Equity Facility, or June 2025 Private Placement) could cause the stock price to decline.

Future Outlook

The company expects to continue incurring significant expenses and operating losses as it advances elraglusib through development, seeks regulatory approval, and potentially commercializes it. Future plans include advancing a Phase 2 study for elraglusib in Ewing sarcoma in 2026 and a Phase 1 study for an oral tablet formulation in advanced adult cancers, both subject to available funding. Management anticipates that existing cash and cash equivalents will not satisfy operational and capital requirements beyond October 2025, necessitating substantial additional funding in the near term through equity offerings, debt financings, or other capital sources.

Management Comments

• Management anticipates, based on currently proposed plans and assumptions, that our cash and cash equivalents on hand will not satisfy the Company's operational and capital requirements beyond October, 2025.
• Based on the above matters, we have concluded that there is substantial doubt regarding the Company's ability to continue as a going concern for a year from the date these unaudited condensed consolidated financial statements were issued.

Industry Context

The positive Phase 2 results for elraglusib in metastatic pancreatic ductal adenocarcinoma (mPDAC) are a significant development in oncology, particularly for a cancer with a historically poor prognosis. A 37% reduction in the risk of death and improved overall survival rates could position elraglusib as a valuable new treatment option, potentially disrupting the current standard of care. The identification of Ewing sarcoma as another potential indication further highlights the broad applicability of GSK-3 inhibition. However, the biopharmaceutical industry is highly capital-intensive, and the company's severe liquidity issues and going concern warning underscore the challenges faced by clinical-stage companies in bringing novel therapies to market, even with promising clinical data. The need for continuous capital raises is a common theme, but the short cash runway presents an immediate and critical hurdle.

Management Changes

Legal Proceedings

• The company may be involved, from time to time, in legal proceedings and claims arising in the ordinary course of its business, but currently, it is not subject to any pending legal proceedings.

Related Party Transactions

• Bios 2024 Co-Invest, LP, an affiliate of Bios Partners (where Dr. Aaron G.L. Fletcher, Chairman of the Board, is Managing Partner), participated in the June 2025 Private Placement, investing $499,996 for 71,428 shares of common stock and warrants.
• The company has a master service agreement with Pacific BioPharma Logistics, Inc. (PBL), where Mr. Richard Kenley, Vice President of Manufacturing, is an unpaid advisor and his spouse is a shareholder. The company incurred $546,892 in services from PBL for the six months ended June 30, 2025, and had an outstanding balance of $40,488 owed to PBL as of June 30, 2025.

Stakeholder Impact

• Shareholders face significant dilution risk from ongoing and future capital raises (e.g., Committed Equity Facility, Private Placement).
• Shareholders face substantial risk of losing all or part of their investment due to the 'going concern' doubt and the company's limited cash runway.
• Employees and consultants may experience program delays or increased compensation costs if the company cannot secure additional funding.
• Creditors (e.g., UIC for license payable, PBL for services) face increased risk due to the company's precarious financial position and going concern warning.
• Patients and the medical community could benefit significantly from elraglusib's promising clinical results in mPDAC, but its availability is contingent on the company's ability to secure funding and achieve regulatory approval.

Next Steps

• Advance the clinical program for elraglusib towards a Phase 2 study in children, adolescents, and adults with relapsed/refractory Ewing sarcoma (EWS) in 2026, subject to available funding.
• Plan a Phase 1 study (Actuate-2401) to identify the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) for the Elraglusib Oral Tablet in patients with advanced, refractory adult cancers, subject to future funding.
• Seek substantial additional funding in the near term through equity offerings, debt financings, or other capital sources to support continuing operations and business strategy.
• Continue to utilize the Committed Equity Facility with B. Riley Principal Capital II to raise capital.
• Keep the registration statement for resale of shares and warrants from the June 2025 Private Placement effective.

Key Dates

Recommendation

Despite highly promising Phase 2 clinical trial results for elraglusib in metastatic pancreatic cancer, the company's severe financial distress, including an explicit 'going concern' warning and a cash runway only until October 2025, presents an immediate and existential threat. While the clinical data is a significant positive, the company's ability to capitalize on this breakthrough is severely hampered by its liquidity crisis. A seasoned investor would prioritize capital preservation given the high probability of further dilution, potential operational curtailment, or even cessation of operations if substantial near-term funding is not secured. The immediate financial risk outweighs the long-term clinical potential at this juncture.

Keywords

elraglusib, pancreatic cancer, mPDAC, GSK-3 inhibitor, clinical trial results, oncology, biopharmaceutical, SEC filing, 10-Q, going concern, capital raise, Ewing sarcoma, Phase 2, survival data